Jiafang He - Concepedia

Author

Jiafang He

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

He, Jiafang, Jiafang He

Publications

440

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Jiafang He is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	265
2	Pharmacology	5	5	265
3	Biochemistry	2	2	36
4	Diabetes	1	1	167
5	Drug Development	1	1	167

Jiafang He

Publications

428

Citations

H-Index

Page 1

	Year	Citations
Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes Tesfaye Biftu, Ranabir SinhaRoy, Ping Chen, Journal of Medicinal Chemistry Medicinal ChemistryScientific RationaleAvailable Dpp-4 InhibitorsDiabetes ManagementClinical Therapeutic	2014	167
(2<i>S</i>,3<i>S</i>)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-<i>N,N</i>-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-<i>a</i>]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes Scott D. Edmondson, Anthony Mastracchio, Robert J. Mathvink, Journal of Medicinal Chemistry	2006	121
4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors Emma R. Parmee, Jiafang He, Anthony Mastracchio, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicine4-Amino Cyclohexylglycine AnaloguesPeptoidPeptide Synthesis	2003	45
3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists Shawn P. Walsh, Alexandra Severino, Changyou Zhou, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryFunctional SelectivityMedicineGpr40 Agonists	2011	25
Isolation, Characterization, and Biological Evaluation of<i>Syn</i>and<i>Anti</i>Diastereomers of [<sup>99m</sup>Tc]Technetium Depreotide: a Somatostatin Receptor Binding Tumor Imaging Agent John E. Cyr, Daniel A. Pearson, Carol A. Nelson, Journal of Medicinal Chemistry	2007	24
Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition Weiguo Liu, Pengcheng P. Shao, Gui‐Bai Liang, ACS Medicinal Chemistry Letters	2018	18
Tetrahydroisoquinoline derivatives containing a benzenesulfonamide moiety as potent, selective human β3 adrenergic receptor agonists Emma R. Parmee, Linda Brockunier, Jiafang He, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicineBenzenesulfonamide MoietyMechanism Of ActionPharmacological Agent	2000	17
Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists Gregori J. Morriello, Harvey R. Wendt, Alka Bansal, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyBiochemistryMedicineRational Drug DesignReceptor (Biochemistry)	2010	11

Page 1